Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Poly ADP-Ribose Polymerase (PARP) Inhibitor Global Market Report 2025
Request Sample Buy Now
Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Poly ADP-Ribose Polymerase (PARP) Inhibitor Global Market Report 2025

By Drug Type (Talazoparib, Veliparib, Olaparib, Other Drug Types), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels), By Application (Ovarian Cancer, Breast Cancer, Other Applications), By End Users (Hospitals, Homecare, Specialty Clinics, Other End Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Overview

• Poly ADP-Ribose Polymerase (PARP) Inhibitor market size has reached to $8.39 billion in 2024

• Expected to grow to $13.81 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%

• Growth Driver: Surging Prevalence Of Ovarian Cancer Fuels Growth In The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

• Market Trend: Tailored Therapy For Genetic Mutation-Driven Cancers

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?

Poly ADP-ribose polymerase (PARP) inhibitors are a class of pharmacological inhibitors that block the enzyme PARP, which is involved in deoxyribonucleic acid (DNA) repair. These inhibitors treat cancers with defects in other DNA repair pathways, preventing cancer cells from repairing damaged DNA and leading to their death.

The main drug types of poly ADP-ribose polymerase (PARP) inhibitor are talazoparib, veliparib, olaparib, and others. Talazoparib refers to a potent PARP inhibitor utilized in cancer therapy by disrupting DNA repair mechanisms in cancer cells. These are sold through various channels, including hospital pharmacies, online pharmacies, retail pharmacies, and others. These inhibitors have found applications in Ovarian Cancer, breast cancer, and others and are used by several end users, such as hospitals, homecare, specialty clinics, and others.

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Size and growth rate 2025 to 2029: Graph

What Is The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Size 2025 And Growth Rate?

The poly ADP-ribose polymerase (PARP) inhibitor market size has grown rapidly in recent years. It will grow from $8.39 billion in 2024 to $9.28 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to clinical research, regulatory approvals, market competition, drug combinations, and patient advocacy.

What Is The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Growth Forecast?

The poly ADP-ribose polymerase (PARP) inhibitor market size is expected to see rapid growth in the next few years. It will grow to $13.81 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to expanded indications, personalized medicine, biomarker development, health economics, and emerging markets. Major trends in the forecast period include precision medicine, immunotherapy advancements, targeted therapies, artificial intelligence in drug discovery, and patient-centric healthcare.

The forecast of 10.4% growth over the next five years reflects a modest reduction of 1.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper ovarian cancer treatment by increasing the cost of PARP inhibitor therapies and genetic testing kits sourced from Switzerland and Spain, thereby delaying targeted therapy initiation and elevating gynecologic oncology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Segmented?

1) By Drug Type: Talazoparib, Veliparib, Olaparib, Other Drug Types

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Ovarian Cancer, Breast Cancer, Other Applications

4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Talazoparib: Talazoparib For Breast Cancer, Talazoparib For Ovarian Cancer, Talazoparib For Prostate Cancer, Talazoparib For Other Cancers

2) By Veliparib: Veliparib For Breast Cancer, Veliparib For Ovarian Cancer, Veliparib For Non-Small Cell Lung Cancer (Nsclc), Veliparib For Other Cancers

3) By Olaparib: Olaparib For Breast Cancer (Her2-negative), Olaparib For Ovarian Cancer (Brca-mutated), Olaparib For Prostate Cancer (Brca-Mutated), Olaparib For Pancreatic Cancer (Brca-Mutated), Olaparib For Other Cancers

4) By Other Drug Types: Niraparib, Rucaparib, Pembrolizumab (Combination Therapy With Parp Inhibitors), Other Parp Inhibitors (Emerging Drugs In Clinical Trials)

What Is Driving The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market? Surging Prevalence Of Ovarian Cancer Fuels Growth In The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market

The increasing prevalence of ovarian cancer is expected to propel the growth of the poly ADP-ribose polymerase (PARP) inhibitor market going forward. Ovarian cancer refers to a malignant tumor that develops in one or both of a woman's ovaries, which are part of the female reproductive system responsible for producing eggs and female hormones. Ovarian cancer is growing due to impact of genetic predisposition, an aging population, environmental exposures, and hormonal imbalances. Poly ADP-Ribose Polymerase (PARP) Inhibitors are used in ovarian cancer treatment to target DNA repair mechanisms, specifically in patients with BRCA mutations, leading to synthetic lethality and enhanced tumor cell death. For instance, in February 2024, according to the World Ovarian Cancer Coalition, a Canada-based non-profit organization, the number of women dying from ovarian cancer per year is projected to increase to 350,956 an increase of almost 70% from 2022. Therefore, the increasing prevalence of ovarian cancer is driving the growth of the poly ADP-ribose polymerase (PARP) inhibitor industry.

Who Are The Major Players In The Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?

Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc

What Are The Key Trends Of The Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market? Tailored Therapy For Genetic Mutation-Driven Cancers

Major companies operating in the poly ADP-ribose polymerase (PARP) inhibitor market are developing generic PARP inhibitors to offer a tailored treatment approach for cancer patients with specific genetic mutations. Generic PARP inhibitors are medications that block the activity of the enzyme poly ADP-ribose polymerase (PARP). For instance, in March 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Olaparib, a PARP inhibitor under the IBYRA brand, aiming to enhance accessibility to advanced cancer treatment. IBYRA targets specific genetic mutations found in breast, ovarian, prostate, and pancreatic cancers, offering a tailored and effective treatment approach. The drug is particularly beneficial for patients with HRD-positive or BRACA mutations, helping to delay disease progression.

Need data on a specific region in this market?
Request Customisation

What Are Latest Mergers And Acquisitions In The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market? Ariceum Therapeutics Expands Radiopharmaceutical Portfolio Through Acquisition Of Theragnostics Ltd.

In June 2023, Ariceum Therapeutics GmbH, a Germany-based radiopharmaceutical company, acquired Theragnostics Ltd. for $41.5 million. With this acquisition, Ariceum Therapeutics significantly enhanced its radiopharmaceutical portfolio, gaining access to novel PARP inhibitor radiation therapies. Theragnostics Ltd. is a UK-based biotechnology company that develops radio-labeled PARP inhibitors to diagnose and treat tumors.

What Is The Regional Outlook For The Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?

North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?

The poly ADP-ribose polymerase (PARP) inhibitor market consists of revenues earned by entities by providing services such as diagnostic tests, clinical trials, consulting services, and patient support programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The poly ADP-ribose polymerase (PARP) inhibitor market also includes sales of test kits, laboratory equipment, imaging systems, sample processing instruments, reagents, and chemicals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Poly ADP-Ribose Polymerase (PARP) Inhibitor Industry?

The poly adp-ribose polymerase (parp) inhibitor market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the poly adp-ribose polymerase (parp) inhibitor industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $9.28 billion
Revenue Forecast In 2034 $13.81 billion
Growth Rate CAGR of 10.4% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Type: Talazoparib, Veliparib, Olaparib, Other Drug Types
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Ovarian Cancer, Breast Cancer, Other Applications
4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments: 1) By Talazoparib: Talazoparib For Breast Cancer, Talazoparib For Ovarian Cancer, Talazoparib For Prostate Cancer, Talazoparib For Other Cancers
2) By Veliparib: Veliparib For Breast Cancer, Veliparib For Ovarian Cancer, Veliparib For Non-Small Cell Lung Cancer (Nsclc), Veliparib For Other Cancers
3) By Olaparib: Olaparib For Breast Cancer (Her2-negative), Olaparib For Ovarian Cancer (Brca-mutated), Olaparib For Prostate Cancer (Brca-Mutated), Olaparib For Pancreatic Cancer (Brca-Mutated), Olaparib For Other Cancers
4) By Other Drug Types: Niraparib, Rucaparib, Pembrolizumab (Combination Therapy With Parp Inhibitors), Other Parp Inhibitors (Emerging Drugs In Clinical Trials)
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Characteristics

3. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Trends And Strategies

4. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Growth Analysis And Strategic Analysis Framework

5.1. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Growth Rate Analysis

5.4. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Total Addressable Market (TAM)

6. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Segmentation

6.1. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Talazoparib

Veliparib

Olaparib

Other Drug Types

6.2. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

Other Distribution Channels

6.3. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Ovarian Cancer

Breast Cancer

Other Applications

6.4. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Homecare

Specialty Clinics

Other End Users

6.5. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Sub-Segmentation Of Talazoparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Talazoparib For Breast Cancer

Talazoparib For Ovarian Cancer

Talazoparib For Prostate Cancer

Talazoparib For Other Cancers

6.6. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Sub-Segmentation Of Veliparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Veliparib For Breast Cancer

Veliparib For Ovarian Cancer

Veliparib For Non-Small Cell Lung Cancer (Nsclc)

Veliparib For Other Cancers

6.7. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Sub-Segmentation Of Olaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Olaparib For Breast Cancer (Her2-negative)

Olaparib For Ovarian Cancer (Brca-mutated)

Olaparib For Prostate Cancer (Brca-Mutated)

Olaparib For Pancreatic Cancer (Brca-Mutated)

Olaparib For Other Cancers

6.8. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Niraparib

Rucaparib

Pembrolizumab (Combination Therapy With Parp Inhibitors)

Other Parp Inhibitors (Emerging Drugs In Clinical Trials)

7. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Regional And Country Analysis

7.1. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

8.1. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

9.1. China Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview

9.2. China Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

10.1. India Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

11.1. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview

11.2. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

12.1. Australia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

13.1. Indonesia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

14.1. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview

14.2. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

15.1. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview

15.2. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

16.1. UK Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

17.1. Germany Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

18.1. France Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

19.1. Italy Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

20.1. Spain Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

21.1. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview

21.2. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

22.1. Russia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

23.1. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview

23.2. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

24.1. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview

24.2. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

25.1. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview

25.2. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

26.1. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview

26.2. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

27.1. Brazil Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

28.1. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview

28.2. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

29.1. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview

29.2. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Competitive Landscape And Company Profiles

30.1. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Competitive Landscape

30.2. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Other Major And Innovative Companies

31.1. Sanofi S.A.

31.2. AstraZeneca plc

31.3. GlaxoSmithKline plc.

31.4. Takeda Pharmaceutical Company Limited

31.5. Merck KGaA

31.6. Teva Pharmaceutical Industries Ltd.

31.7. Daiichi Sankyo Company Limited

31.8. Eisai Co. Ltd.

31.9. Ipsen Biopharmaceuticals Inc.

31.10. Genentech Inc.

31.11. BioMarin Pharmaceutical Inc.

31.12. Seattle Genetics Inc.

31.13. Medivation Inc.

31.14. Myriad Genetics Inc.

31.15. PharmaMar S.A.

32. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

34. Recent Developments In The Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

35. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market High Potential Countries, Segments and Strategies

35.1 Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market In 2029 - Countries Offering Most New Opportunities

35.2 Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market In 2029 - Segments Offering Most New Opportunities

35.3 Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Sub-Segmentation Of Talazoparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Sub-Segmentation Of Veliparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Sub-Segmentation Of Olaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Pfizer Inc. Financial Performance
  • Table 80: Johnson & Johnson Services Inc. Financial Performance
  • Table 81: AbbVie Inc. Financial Performance
  • Table 82: Bayer AG Financial Performance
  • Table 83: Novartis AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Sub-Segmentation Of Talazoparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Sub-Segmentation Of Veliparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Sub-Segmentation Of Olaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Pfizer Inc. Financial Performance
  • Figure 80: Johnson & Johnson Services Inc. Financial Performance
  • Figure 81: AbbVie Inc. Financial Performance
  • Figure 82: Bayer AG Financial Performance
  • Figure 83: Novartis AG Financial Performance

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

Read More About Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Read More About Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

Read More About A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Read More About A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Read More About A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

A forward-looking 2025 report detailing projections, service trends and operational models in the medical accompaniment service market.

Read More About A forward-looking 2025 report detailing projections, service trends and operational models in the medical accompaniment service market.

Cyber Security Managed Services Global Market Report 2025 – By Service (Managed Detection And Response (MDR), Incident Management, Managed Vulnerability, Identity And Access Solution, Other Services), By Security Type (N...

View Report

Cytotoxic Drugs Global Market Report 2025 – By Drug Type (Alkylating Agents, Antitumor Antibiotics, Antimetabolites, Plant Alkaloids, Other Drug Types), By Therapy (Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Tr...

View Report

Data Compression Software Global Market Report 2025 – By Type (Lossless Compression, Lossy Compression), By Service (Professional Service, Support And Maintenance Service), By Deployment (Cloud, On-Premise), By Vertical ...

View Report

Automotive Tire Global Market Report 2025 – By Rim Size (Less Than 15 Inches, 15 to 20 Inches, More Than 20 Inches), By Vehicle Type (Passenger Vehicle, Commercial Vehicle, Electric Vehicle), By Manufacturing (Radial Tir...

View Report

Two Wheeler Lead Acid Batteries Global Market Report 2025 – By Type (Valve Regulated Lead Acid (VRLA) Batteries, Flooded), By Capacity (Less Than 5 Ampere Hour, 5 Ampere Hour To 10 Ampere Hour, 10 Ampere Hour To 20 Amper...

View Report

Eyewear Global Market Report 2025 – By Product (Contact Lenses, Spectacles, Sunglasses), By Gender (Men, Women, Unisex), By Distribution Channel (Optical Stores, Independent Brand Showrooms, Online Stores, Retail Stores)...

View Report

Nucleic Acid Based Gene Therapy Global Market Report 2025 – By Technology (Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies), By App...

View Report

Frequently Asked Questions

Poly ADP-ribose polymerase (PARP) inhibitors are a class of pharmacological inhibitors that block the enzyme PARP, which is involved in deoxyribonucleic acid (DNA) repair. These inhibitors treat cancers with defects in other DNA repair pathways, preventing cancer cells from repairing damaged DNA and leading to their death. For further insights on this market, request a sample here

The market major growth driver - Surging Prevalence Of Ovarian Cancer Fuels Growth In The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market. For further insights on this market, request a sample here

The poly adp-ribose polymerase (parp) inhibitor market size has grown rapidly in recent years. It will grow from $8.39 billion in 2024 to $9.28 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to clinical research, regulatory approvals, market competition, drug combinations, and patient advocacy. The poly adp-ribose polymerase (parp) inhibitor market size is expected to see rapid growth in the next few years. It will grow to " $13.81 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to expanded indications, personalized medicine, biomarker development, health economics, and emerging markets. Major trends in the forecast period include precision medicine, immunotherapy advancements, targeted therapies, artificial intelligence in drug discovery, and patient-centric healthcare. For further insights on this market, request a sample here

The poly adp-ribose polymerase (parp) inhibitormarket covered in this report is segmented –
1) By Drug Type: Talazoparib; Veliparib; Olaparib; Other Drug Types
2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels
3) By Application: Ovarian Cancer; Breast Cancer; Other Applications
4) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users Subsegments:
1) By Talazoparib: Talazoparib For Breast Cancer; Talazoparib For Ovarian Cancer; Talazoparib For Prostate Cancer; Talazoparib For Other Cancers
2) By Veliparib: Veliparib For Breast Cancer; Veliparib For Ovarian Cancer; Veliparib For Non-Small Cell Lung Cancer (Nsclc); Veliparib For Other Cancers
3) By Olaparib: Olaparib For Breast Cancer (Her2-negative); Olaparib For Ovarian Cancer (Brca-mutated); Olaparib For Prostate Cancer (Brca-Mutated); Olaparib For Pancreatic Cancer (Brca-Mutated); Olaparib For Other Cancers
4) By Other Drug Types: Niraparib; Rucaparib; Pembrolizumab (Combination Therapy With Parp Inhibitors); Other Parp Inhibitors (Emerging Drugs In Clinical Trials) For further insights on this market, request a sample here

North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc . For further insights on this market, request a sample here.

Major trends in this market include Tailored Therapy For Genetic Mutation-Driven Cancers. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon